Analysis patients with a previous ischemic stroke or TIA were randomly allocated to groups
given ASA (50 mg) daily either with modified-release dipyridamole (400 mg) or alone. 3 The …

Patients suffering from transient ischemic attack (TIA) or ischemic stroke have a high risk of
suffering a first or recurrent stroke, with an annual risk of between 5 and 15%. The European …

In a post hoc analysis of the European Stroke Prevention Study 2 (ESPS2), we investigated
whether dipyridamole given as antiplatelet drug in patients with TIA or stroke increases the …

Background and Purpose—Results from randomized controlled trials of dipyridamole, given
with or without aspirin, for secondary prevention after ischemic stroke or transient ischemic …

In 1988, an optimal antiplatelet regimen for secondary stroke prevention remained to be
defined. We undertook a randomised, placebo‐controlled, double‐blind trial to investigate …

Background: Approximately 25% of strokes are recurrent. Antiplatelet therapy is indicated for
the prevention of recurrent stroke in patients with a history of noncardioembolic minor stroke …

Background and Purpose—This meta-analysis systematically reviewed randomized
controlled trials comparing aspirin plus dipyridamole with aspirin alone in patients with …

Objectives: To study the effect of combination therapy with aspirin and dipyridamole (A+ D)
over aspirin alone (ASA) in secondary prevention after transient ischaemic attack (TIA) or …

In 1988, we undertook a randomized, placebo-controlled, double-blind trial to investigate the
safety and efficacy of low-dose acetylsalicylic acid (ASA), modified-release dipyridamole …

Background—Patients enrolled in clinical trials after nondisabling cerebral ischemia have
an annual risk of vascular events (death from all vascular causes, nonfatal stroke, or nonfatal …